Advertisement

Adjuvant Treatment of Gastric Cancer

  • J. A. Wils
Conference paper

Abstract

The incidence of gastric cancer has declined over the last 50 years in the western world, especially in the United States. The decline has been very steep—from 30 in 100,000 to 8 in 100,000—and for the most part has occurred in older people and in the white population. Gastric cancer now ranks as the sixth most common cause of death from cancer. In Western Europe the incidence is still around 20 in 100,000, while a higher incidence is found in Japan, South America (especially Chile), Eastern Europe, Spain, and Portugal. The downward trend, however, has been generally uniform, and even in Japan the incidence appears to be declining.

Keywords

Gastric Carcinoma Median Survival Time Eastern Cooperative Oncology Group Advanced Gastric Cancer South West Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dixon WJ, Longmire WP, Holden WD: Use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric and colorectal carcinoma: ten year follow up. Ann Surg 1971; 173: 16.CrossRefGoogle Scholar
  2. 2.
    Serlin O, Wolkoff JS, Amadeo JH, et al: Use of 5-fluorodeoxyuridine (FudR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1969; 24: 223.PubMedCrossRefGoogle Scholar
  3. 3.
    Higgings GA, Amadeo JH, Smith DE, et al: Efficiency of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 1983; 52: 1105.CrossRefGoogle Scholar
  4. 4.
    The Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection of gastric cancer. Cancer 1982; 49: 1116.CrossRefGoogle Scholar
  5. 5.
    Engstrom PF, Levin PT, Douglass HO, et al: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cancer 1985; 55: 1868.PubMedCrossRefGoogle Scholar
  6. 6.
    Schlag P, Schreml W, Gaus W. et al: Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results, in Recent Results in Cancer Research. BerlinHeidelberg-New York, Springer, 1982, p 277.Google Scholar
  7. 7.
    Macdonald JS, Schein PS, Woolley PV, et al: 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533.PubMedGoogle Scholar
  8. 8.
    Bitran JD, Desser RK, Kozloff MF, et al: Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-fluorouracil, Adriamycin and mitomycin C (FAM). Cancer Treatm Rep 1979; 63: 2049.Google Scholar
  9. 9.
    Gagliano R, McCracken JD, Chen T: Adjuvant chemotherapy with 5-fluorouracil, Adriamycin and mitomycin (FAM) in gastric cancer—A SWOG study, abstract. Proc ASCO 1983; 2: 114.Google Scholar
  10. 10.
    Coombes RC, Schein PS, Chilvers C, et al: A controlled trial of FAM (5-FU, Adriamycin, mitomycin-C) chemotherapy as adjuvant treatment for resected gastric carcinoma, abstract. Cancer Chemother Pharmacol 1986; 18 (suppl 1): 20.Google Scholar
  11. 11.
    Douglass HO, Lavin PT, Goudsmit A, et al: An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin-C, Adriamycin and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984; 2: 1372.PubMedGoogle Scholar
  12. 12.
    Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. JAMA 1985; 253: 2061.Google Scholar
  13. 13.
    De Lisi V, Cocconi G, Tonato M, et al: Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin and mitomycin (BAFMi) in the treatment of advanced gastric cancer. A phase III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treatm Rep 1986; 70: 481.Google Scholar
  14. 14.
    Wils J: Current status of chemotherapy for advanced gastric cancer. Anticancer Res 1987; 7: 755.PubMedGoogle Scholar
  15. 15.
    Preusser P, Wilke H, Achterrath W, et al: Advanced gastric carcinoma. A phase II study with etoposide (E), adriamycin (A) and split course cisplatin (P) = EAP, abstract. Proc ASCO 1987; 6: 75.Google Scholar
  16. 16.
    Klein HO, Dias Wickramanayake P, Farrokh G-H: 5-Fluorouracil (5-FU), adriamycin (ADM) and methotrexate (MTX)—a combination protocol (FAMTX) for treatment of metastasized stomach cancer, abstract. Proc ASCO 1986; 5: 84.Google Scholar
  17. 17.
    Wils J, Bleiberg H, Blijham G, et al: An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate (MTX) and 5-fluorouracil (F), combined with adriamycin (A) (FAMTX) in advanced measurable gastric cancer. J Clin Oncol 1986; 4: 1799.PubMedGoogle Scholar
  18. 18.
    Killen JY, Ellenberg SS, Friedman MA: Combination chemotherapy (CT) regimens in advanced gastric cancer (GC), abstract. Proc ASCO 1985; 4: 82.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1989

Authors and Affiliations

  • J. A. Wils

There are no affiliations available

Personalised recommendations